Adrian V. Lee

Active 1972–2025

168
Papers
20,054
Citations
85
h-index
151
i10-index

Citations

Citations per year for Adrian V. Lee1973: 2 citations1974: 2 citations1976: 1 citations1977: 3 citations1978: 1 citations1979: 1 citations1980: 1 citations1981: 1 citations1982: 3 citations1983: 6 citations1984: 2 citations1985: 1 citations1986: 7 citations1987: 6 citations1988: 26 citations1989: 14 citations1990: 28 citations1991: 43 citations1992: 29 citations1993: 37 citations1994: 28 citations1995: 31 citations1996: 17 citations1997: 25 citations1998: 24 citations1999: 31 citations2000: 69 citations2001: 70 citations2002: 52 citations2003: 91 citations2004: 93 citations2005: 116 citations2006: 114 citations2007: 120 citations2008: 147 citations2009: 124 citations2010: 131 citations2011: 154 citations2012: 138 citations2013: 129 citations2014: 122 citations2015: 96 citations2016: 92 citations2017: 103 citations2018: 142 citations2019: 507 citations2020: 671 citations2021: 727 citations2022: 607 citations2023: 421 citations2024: 776 citations2025: 376 citations2026: 23 citations1975: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,695 citing papers, 30.2% of this breakdownChina: 1,326 citing papers, 14.9% of this breakdownUnited Kingdom: 495 citing papers, 5.5% of this breakdownGermany: 361 citing papers, 4% of this breakdownItaly: 355 citing papers, 4% of this breakdownCanada: 321 citing papers, 3.6% of this breakdownAustralia: 268 citing papers, 3% of this breakdownFrance: 249 citing papers, 2.8% of this breakdownJapan: 237 citing papers, 2.7% of this breakdownNetherlands: 185 citing papers, 2.1% of this breakdownSpain: 178 citing papers, 2% of this breakdownSwitzerland: 155 citing papers, 1.7% of this breakdown
0%30.2%Other 23.5%

Fields

  • Biochemistry, Genetics and Molecular Biology46.9%
  • Medicine41.9%
  • Immunology and Microbiology3.2%
  • Computer Science2.6%
  • Agricultural and Biological Sciences1.1%
  • Neuroscience0.9%
  • Other3.4%

Topics

  • Cancer Genomics and Diagnostics3.7%
  • Cancer Cells and Metastasis3%
  • Helicobacter pylori-related gastroenterology studies3%
  • Estrogen and related hormone effects3%
  • Ferroptosis and cancer prognosis2.8%
  • Cancer Immunotherapy and Biomarkers2.3%
  • Other82.2%

Coauthors

All papers

Open in search
  1. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Todd Pihl, Qiang Sun, Yunhu Wan, Ye Wu, Juok Cho, Timothy Defreitas, Scott Frazer, Nils Gehlenborg, Gad Getz, David I. Heiman, Jaegil Kim, Michael S. Lawrence, Pei Lin, Sam Meier, Michael S. Noble, Gordon Saksena, Doug Voet, Hailei Zhang, Brady Bernard, Nyasha Chambwe, Varsha Dhankani, Theo Knijnenburg, Roger Kramer, Kalle Leinonen, Yuexin Liu, Michael B. Miller, Sheila M. Reynolds, Ilya Shmulevich, Vesteinn Thorsson, Wei Zhang, Rehan Akbani, Bradley M. Broom, Apurva M. Hegde, Zhenlin Ju, Rupa S. Kanchi, Anil Korkut, Jun Li, Han Liang, Shiyun Ling, Wenbin Liu, Yiling Lu, Gordon B. Mills, Kwok-Shing Ng, Arvind Rao, Michael Ryan, Jing Wang, John N. Weinstein, Jiexin Zhang, Adam Abeshouse, Joshua Armenia, Debyani Chakravarty, Walid K. Chatila, Ino de Bruijn, Galen F. Gao, Benjamin E. Gross, Zachary Heins, Ritika Kundra, Konnor La, Marc Ladanyi, Augustin Luna, Moriah G. Nissan, Angelica Ochoa, Sarah Phillips, Ed Reznik, Francisco Sánchez-Vega, Chris Sander, Nikolaus Schultz, Robert E. Sheridan, S. Onur Sumer, Yichao Sun and 640 more - Cell 2018 cited by 4,018

  2. The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes

    Authors: , , , , , , - Cancer Discovery 2022 cited by 206

  3. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kenneth Ng, Juliana Eng, Isabel R. Preeshagul, W. Victoria Lai, John J. Fiore, Afsheen N. Iqbal, Daniela Molena, Gaetano Rocco, Bernard J. Park, Lee P. Lim, Mark Junjie Li, Candace Tong-Li, Madhawa De Silva, David Chan, Connie I. Diakos, Malinda Itchins, Stephen Clarke, Nick Pavlakis, Adrian V. Lee, Natasha Rekhtman, Jason C. Chang, William D. Travis, Gregory J. Riely, David B. Solit, Mithat Gönen, Valerie W. Rusch, Andreas Rimner, Daniel R. Gomez, Alexander Drilon, Howard I. Scher, Sohrab P. Shah, Michael F. Berger, Maria E. Arcila, Marc Ladanyi, Ross L. Levine, Ronglai Shen, Pedram Razavi, Jorge S. Reis‐Filho, David R. Jones, Charles M. Rudin, James M. Isbell, Bob T. Li - Nature Medicine 2022 cited by 185

  4. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Julie M. Gastier‐Foster, Mothaffar F. Rimawi, Rita Nanda, Nancy U. Lin, Claudine Isaacs, P. Kelly Marcom, Anna Maria Storniolo, Fergus J. Couch, Uma Chandran, Michael A. Davis, Jonathan C. Silverstein, Alexander J. Ropelewski, Minetta C. Liu, Susan G. Hilsenbeck, Larry Norton, Andrea L. Richardson, W. Fraser Symmans, Antonio C. Wolff, Nancy E. Davidson, Lisa A. Carey, Adrian V. Lee, Justin M. Balko, Katherine A. Hoadley, Peter W. Laird, Elaine R. Mardis, Tari A. King, AURORA US Network, Aguirre A. de Cubas, Charles M. Perou - Nature Cancer 2022 cited by 114

  5. Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer

    Authors: , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2022 cited by 80

  6. Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)

    Authors: , , , , , , , , , , , , , , , , , , , - Therapeutic Advances in Medical Oncology 2023 cited by 39

  7. Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation

    Authors: , , - Frontiers in Endocrinology 2015 cited by 185

  8. Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment

    Authors: , , , , , , , , , , , , , , , , - Nature Cancer 2023 cited by 76

  9. Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities

    Authors: , , , , , , , , , , , , , , , , , , - Nature Communications 2022 cited by 96

  10. Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Paul Jank, Carsten Denkert, Maria Margarete Karsten, Jens‐Uwe Blohmer, Ben Ho Park, Peter C. Lucas, Jennifer M. Atkinson, Adrian V. Lee, Steffi Oesterreich - Cancer Research 2022 cited by 85

  11. Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2019 cited by 124

  12. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases

    Authors: , , , , , , , , , , , , , , , , , - JAMA Oncology 2016 cited by 171

  13. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2022 cited by 72

  14. Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2018 cited by 129

  15. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients

    Authors: , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2015 cited by 204

  16. Circulating Tumor Cell Phenotyping via High‐Throughput Acoustic Separation

    Authors: , , , , , , , , , , , , - Small 2018 cited by 173

  17. The Cellular Origin and Evolution of Breast Cancer

    Authors: , , - Cold Spring Harbor Perspectives in Medicine 2017 cited by 87

  18. Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis

    Authors: , , , , , - Clinical Cancer Research 2019 cited by 58

  19. Single cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine

    Authors: , , , , , , , , , , , , , - Annals of Oncology 2022 cited by 31

  20. Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy

    Authors: , , , , - Journal of Clinical Oncology 2005 cited by 520

  21. Estrogen Receptor–Positive, Progesterone Receptor–Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance

    Authors: , , , , , , - JNCI Journal of the National Cancer Institute 2005 cited by 485

  22. Expression of Autotaxin and Lysophosphatidic Acid Receptors Increases Mammary Tumorigenesis, Invasion, and Metastases

    Authors: , , , , , , , , , , , , , , , , - Cancer Cell 2009 cited by 397

  23. Loss of E-cadherin Enhances IGF1–IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors

    Authors: , , , , , , , , , , , - Clinical Cancer Research 2018 cited by 86

  24. Anti-epidermal growth factor receptor therapy for glioblastoma in adults

    Authors: , , , , , - Cochrane Database of Systematic Reviews 2020 cited by 37